{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:20:45Z","timestamp":1787833245140,"version":"build-2784847793"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Endocrine receptor-positive (ER+) and HER2-negative breast cancer (BC) represents approximately 80% of all BCs. Most patients are treated with upfront surgery; however, 15%\u201330% will develop late recurrences. Genomic assay indication is usually based on postoperative pathological data including histology subtype, tumor size, lymph node status, SBR grade, and Ki67. Performing genomic testing on core needle biopsy specimens prior to surgery may offer several advantages. In this manuscript, we assess the feasibility, reliability, utility, and potential benefits of such genomic analyses performed on core needle biopsies. Several factors may lead to proposing genomic assay analysis on biopsy: (1) optimization of the patient pathway by reducing time to therapeutic decision-making, (2) predicting response to neoadjuvant chemotherapy (NAC) or neoadjuvant endocrine therapy (NET), and (3) refining prognostic assessment to guide adjuvant chemotherapy decisions in patients for whom axillary surgery is not planned. Given the feasibility and reliability of genomic assay on core needle biopsies, it can be suggested that this practice may become more common in the near future. Knowledge of the evolutive risk determined by the result of genomic assay, as well as clinicopathological characteristics, allows more precise personalization of the therapeutic strategy, including the choice between upfront surgery and neoadjuvant therapy, the selection of systemic treatments, and decision-making in the absence of axillary staging.<\/jats:p>","DOI":"10.3389\/fonc.2026.1892354","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:53:45Z","timestamp":1787831625000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility, reliability, and clinical value of genomic assay on pre-therapeutic biopsy for endocrine receptor-positive HER2-negative early breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Gilles","family":"Houvenaeghel","sequence":"first","affiliation":[{"name":"Department of Gynecology, Hopital Europ\u00e9en","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Souquet Bressand","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hopital Europ\u00e9en","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Juhan Duguet","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hopital Europ\u00e9en","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Institut Paoli Calmettes","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bouteille","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Institut Paoli Calmettes","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sabiani","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Hopital de la Conception, Assistance Publique- H\u00f4pitaux de Marseille (AP-HM)","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Barrou","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Hopital Europ\u00e9en","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Juquel","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hopital Europ\u00e9en","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Brunel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hopital Europ\u00e9en","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Quilichini","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Hopital Europ\u00e9en","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2018.03.002","article-title":"Global analysis of advanced\/ metastatic breast cancer: decade report (2005\u20132015)","volume":"39","author":"Cardoso","year":"2018","journal-title":"Breast"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13813","article-title":"Real-world clinical outcomes in biological subgroups of breast cancer in the hospital district of Southwest Finland","volume":"26","author":"Teerenhovi","year":"2021","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.36469\/001c.137277","article-title":"Size and treatment outcomes of HR+, HER2- early breast cancer population with high risk of recurrence: a real-world cohort study with Danish Breast Cancer Cooperative Group registry data","volume":"12","author":"Loponen","year":"2025","journal-title":"J Health Econ Outcomes Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0310","article-title":"A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer","volume":"18","author":"Sheffield","year":"2022","journal-title":"Future Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S310","DOI":"10.1016\/j.annonc.2024.08.177","article-title":"234MO Explaining the relationships between age, endocrine therapy persistence and risk of recurrence in hormone-positive early breast cancer: a nationwide cohort study","volume":"35","author":"Dumas","year":"2024","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.62.6630","article-title":"Prognostic impact of the combination of recurrence score and quantitative estrogen receptor expression (ESR1) on predicting late distant recurrence risk in estrogen receptor-positive breast cancer after 5 years of tamoxifen: results from NRG Oncology\/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14","volume":"34","author":"Wolmark","year":"2016","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.671","article-title":"The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2- breast cancer patients","volume":"109","author":"Dubsky","year":"2013","journal-title":"Br J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02759","article-title":"Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+\/HER2\u2013 early breast cancer","volume":"40","author":"Nitz","year":"2022","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104743","article-title":"189O Ribociclib + endocrine treatment vs SoC chemotherapy in intermediate risk HR+\/HER2- early breast cancer: results from the neoadjuvant cohort of the Phase-III WSG ADAPTcycle\u2013trial","volume":"10","author":"Harbeck","year":"2025","journal-title":"ESMO Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112671","article-title":"The French early breast cancer cohort (FRESH): A resource for breast cancer research and evaluations of oncology practices based on the French national healthcare system database (SNDS)","volume":"14","author":"Dumas","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26050","article-title":"Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test","volume":"122","author":"Jakubowski","year":"2020","journal-title":"J Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0300339","article-title":"A randomised controlled trial of Pre-Operative Oncotype DX testing in early-stage breast cancer (PRE-DX study) - Study protocol","volume":"19","author":"Northgraves","year":"2024","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2063-z","article-title":"Assessment accuracy of core needle biopsy for hormone receptors in breast cancer: a meta\u2010analysis","volume":"135","author":"Li","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4048\/jbc.2017.20.3.297","article-title":"Comparison of core needle biopsy and surgical specimens in determining intrinsic biological subtypes of breast cancer with immunohistochemistry","volume":"20","author":"You","year":"2017","journal-title":"J Breast Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.sabcs11-p3-06-05","article-title":"Comparison of Oncotype DX Recurrence Scores between surgical and core biopsy specimens in breast cancer patients [abstract","volume":"71","author":"Stull","year":"2011","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880244","article-title":"Assessment of pathologic prognostic factors in breast core needle biopsies","volume":"12","author":"Sharifi","year":"1999","journal-title":"Mod Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.143","article-title":"Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR\u2010positive\/HER2\u2010negative breast carcinoma","volume":"110","author":"Daveau","year":"2014","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2005.06.004","article-title":"Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens","volume":"15","author":"Burge","year":"2006","journal-title":"Breast"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00327","article-title":"Concordance analysis of paired breast cancer core needle biopsies and surgical excision samples using the Oncotype DX Breast Recurrence Score\u00ae assay","volume":"9","author":"Nassar","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2012-200716","article-title":"Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections","volume":"65","author":"M\u00fcller","year":"2012","journal-title":"J Clin Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1542","article-title":"Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples","volume":"8","author":"Zanetti-D\u00e4llenbach","year":"2006","journal-title":"Breast Cancer Res"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS25-PS3-08-26","article-title":"Comparison of breast cancer index scores from core-needle biopsies versus surgical excisions in early-stage breast cancer","author":"Kapoor","year":""},{"key":"B27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/jso.26780","article-title":"High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancer","volume":"125","author":"Crozier","year":"2022","journal-title":"J Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-06075-6","article-title":"Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients","volume":"186","author":"Qi","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/bjs\/znaa048","article-title":"Value of a 21-gene expression assay on core biopsy to predict neoadjuvant chemotherapy response in breast cancer: systematic review and meta-analysis","volume":"108","author":"Boland","year":"2021","journal-title":"Br J Surg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.02.0818","article-title":"Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer","volume":"23","author":"Gianni","year":"2005","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0333-1","article-title":"The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer","volume":"119","author":"Straver","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr550","article-title":"Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy","volume":"23","author":"Mathieu","year":"2012","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.09.014","article-title":"EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer","volume":"355","author":"Bertucci","year":"2014","journal-title":"Cancer Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051133","article-title":"Multi-gene prognostic signatures and prediction of pathological complete response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer patients","volume":"12","author":"Mazo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432","article-title":"Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictor","volume":"24","author":"Loibl","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2020.04.020","article-title":"The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial","volume":"134","author":"Dubsky","year":"2020","journal-title":"Eur J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-08039-7","article-title":"Evaluation of the 12-gene molecular score and the 21-gene recurrence score as predictors of response to neo-adjuvant chemotherapy in estrogen receptor-positive, HER2-negative breast cancer","volume":"27","author":"Soliman","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12916-015-0540-z","article-title":"Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy","volume":"13","author":"Prat","year":"2015","journal-title":"BMC Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1078-0432.ccr-15-0630","article-title":"Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the Prosigna Assay","volume":"22","author":"Prat","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0757","article-title":"Subtype-specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer","volume":"22","author":"Callari","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy448","article-title":"Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer","volume":"29","author":"Cottu","year":"2018","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.562","article-title":"Phase II trial evaluating the use of 21-gene recurrence score (RS) to select preoperative therapy in hormone receptor (HR)-positive breast cancer","volume":"31","author":"Zelnak","year":"2013","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24610","article-title":"Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: a multicenter trial","volume":"115","author":"Bear","year":"2017","journal-title":"J Surg Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.15_suppl.e12093","article-title":"Predicting response to neoadjuvant chemotherapy in nonmetastatic hormone receptor-positive breast cancer using 21-gene breast recurrence score test","volume":"37","author":"Thekkekara","year":"2019","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10549-015-3613-y","article-title":"A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score","volume":"154","author":"Yardley","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07555-w","article-title":"Are we overtreating hormone receptor positive breast cancer with neoadjuvant chemotherapy? Role of OncotypeDxV R for hormone receptor positive patients undergoing neoadjuvant chemotherapy","volume":"26","author":"Kantor","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1634\/theoncologist.2014-0198","article-title":"In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy","volume":"20","author":"Pivot","year":"2015","journal-title":"Oncologist"},{"key":"B48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3233\/bd-150199","article-title":"The impact of Onco type DXV R recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer","volume":"36","author":"Soran","year":"2016","journal-title":"Breast Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06269-6","article-title":"Evaluation of risk stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy","volume":"189","author":"Ma","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B50","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10549-006-9366-x","article-title":"Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue","volume":"103","author":"Mina","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9590-z","article-title":"Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients","volume":"108","author":"Chang","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"B52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-011-1683-z","article-title":"A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response","volume":"133","author":"Krijgsman","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2572-4","article-title":"Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neo-adjuvant chemotherapy","volume":"139","author":"Gl\u00fcck","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3908-y","article-title":"Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)","volume":"21","author":"Whitworth","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0163-9","article-title":"Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy","volume":"31","author":"Bayraktar","year":"2014","journal-title":"Med Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clbc.2015.10.004","article-title":"Relative prognostic and predictive value of gene signature and histologic grade in estrogen receptor-positive, HER2-negative breast cancer","volume":"16","author":"Iwamoto","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5600-x","article-title":"Chemosensitivity and endocrine sensitivity in clinical luminal breast cancer patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) predicted by molecular subtyping","volume":"24","author":"Whitworth","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-07107-8","article-title":"Oncotype DX recurrence score as a predictor of response to neoadjuvant chemotherapy","volume":"26","author":"Pease","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1200\/jco.2019.37.15_suppl.578","article-title":"Race and response to neoadjuvant chemotherapy according to MammaPrint risk","volume":"37","author":"Nunes","year":"2019","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"GS4","DOI":"10.1158\/1538-7445.SABCS20-GS4-03","article-title":"Abstract GS4-03: Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+\/HER2- early BC by: Results from the neoadjuvant part of ADAPT HR+\/HER2- trial","volume":"81","author":"Kuemmel","year":"2021","journal-title":"Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e12630","article-title":"21-gene recurrence score assay as a predictor of pathological response in neoadjuvant chemotherapy administration for ER-positive\/HER2-negative early-stage breast cancer","volume":"38","author":"Murillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09382-w","article-title":"The role of Oncotype DX\u00ae recurrence score in predicting axillary response after neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Pardo","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05989-5","article-title":"Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score test in young women with estrogen receptor-positive early breast cancer","volume":"186","author":"Sella","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.09.017","article-title":"Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers","volume":"176","author":"de Nonneville","year":"2022","journal-title":"Eur J Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs15-p5-13-02","article-title":"Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis","volume":"2","author":"Spring","year":"2016","journal-title":"JAMA Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4964-y","article-title":"Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study","volume":"173","author":"Iwata","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2009.03.005","article-title":"21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients","volume":"18","author":"Akashi-Tanaka","year":"2009","journal-title":"Breast"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-013-0614-x","article-title":"Evaluating the 21-gene assay Recurrence Score\u00ae as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer","volume":"19","author":"Ueno","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.04.010","article-title":"Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: a systematic review and meta-analysis","volume":"58","author":"Davey","year":"2021","journal-title":"Breast"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103733","article-title":"Neoadjuvant letrozole and palbociclib in patients with HR-positive\/HER2-negative early breast cancer and Oncotype DX Recurrence Score \u226518: DxCARTES study","volume":"9","author":"Guerrero-Zotano","year":"2024","journal-title":"ESMO Open"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs19-p5-13-02","article-title":"Abstract P5-13-02: neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive\/HER2 negative breast cancer and an oncotype Dx recurrence score (25)","volume":"80","author":"Abu-Khalaf","year":"2020","journal-title":"Canc Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s1470-2045(19)30786-7","article-title":"Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-10-1081","article-title":"Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor\u2013positive breast cancer","volume":"11","author":"Macaskill","year":"2006","journal-title":"Oncologist"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.6950","article-title":"Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031","volume":"29","author":"Ellis","year":"2011","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12972-5","article-title":"Local-regional recurrence after neoadjuvant endocrine therapy: Data from ACOSOG Z1031 (Alliance), a randomized phase 2 neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-positive clinical stage 2 or 3 breast cancer","volume":"30","author":"Hunt","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1159\/000518573","article-title":"Neoadjuvant therapy of cyclin-dependent kinase 4\/6 inhibitors combined with endocrine therapy in HR+\/HER2- breast cancer: a systematic review and meta-analysis","volume":"44","author":"Hong","year":"2021","journal-title":"Oncol Res Treat"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-10459-3","article-title":"Neoadjuvant endocrine therapy as an alternative to neoadjuvant chemotherapy among hormone receptor-positive breast cancer patients: pathologic and surgical outcomes","volume":"28","author":"Cao","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41523-025-00772-5","article-title":"Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+\/HER2- breast cancer","volume":"11","author":"Han","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.3759","article-title":"Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial","volume":"9","author":"Gentilini","year":"2023","journal-title":"JAMA Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2412063","article-title":"Axillary surgery in breast cancer - primary results of the INSEMA trial","volume":"392","author":"Reimer","year":"2025","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12885-018-5227-3","article-title":"Lymph node positivity in different early breast carcinoma phenotypes: a predictive model","volume":"19","author":"Houvenaeghel","year":"2019","journal-title":"BMC Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12193-w","article-title":"How often do sentinel lymph node biopsy results affect adjuvant therapy decisions among postmenopausal women with early-stage HR+\/HER2- breast cancer in the post-RxPONDER era","volume":"29","author":"Pilewskie","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2023.08.037","article-title":"Using MammaPrint on core needle biopsy to guide the need for axillary staging during breast surgery","volume":"175","author":"Drapalik","year":"2024","journal-title":"Surgery"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2024.06.025","article-title":"Can genomic testing help refine choosing wisely the omission of axillary staging in cN0 breast cancer","volume":"301","author":"Fang","year":"2024","journal-title":"J Surg Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-10457-5","article-title":"Is the 21-gene recurrence score on core needle biopsy equivalent to surgical specimen in early-stage breast cancer? A comparison of gene expression between paired core needle biopsy and surgical specimens","volume":"28","author":"Orozco","year":"2021","journal-title":"Ann Surg Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1892354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:53:47Z","timestamp":1787831627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1892354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":85,"alternative-id":["10.3389\/fonc.2026.1892354"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1892354","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1892354"}}